6.61 USD
▼-0.25-3.66%
盘后 6.59 0.00%
2026-09-16
市值
$21.30M
市盈率
—
EPS
-9.73
股息率
—
52 周区间
4.75 – 12.30
成交量
20.32K
Beta
-0.26
目标价
71.50
52W 低 4.7552W 高 12.30
价格走势
公司简介
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated...
关联新闻
- Longeveron explores strategic options after therapy fails mid-stage trial for infant heart condition
Longeveron on Wednesday said it would explore strategic options after its experimental stem cell therapy failed to meet the main goal of a mid-stage trial for a rare infant heart condition.